Slide 1: Corporate Presentation
a oA. EIP PHARMA Corporate Presentation May 11", 2023
Slide 2: Important Additional Information and Where to Find It
‘This communication does not constitute an offer to sell or the solicitation ofan offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qu
Slide 3: Forward-Looking Statements
Forward-Looking Statements ‘This presentation includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding management's intentions, plans, beliefs, expectations or forecasts for the future, including, but no
Slide 4: Planned Merger
a PHARMA Diffusio,n Pharmaceuticals inc. Planned Merger" rd E | Pp Y Diffusion sharehoters wilown22.74% ofthe total nunber of outstanding shares of 3 capil stock of NewCo® mbined company will have a: e 2b clinical asset Merger expected to * Cash runway through Phase 2b data cloee mine Zee and into e
Slide 5: EIP Pharma at a Glance
EIP Pharma at a Glance E | P Late Clinical Stage CNS Company PHARMA Differentiated approach to age-related neurologic disorders with a late-stage lead clinical asset; pipeline of additional indications and second asset Phase 2b Ready Lead Drug Candidate Neflamapimod has the potential to be the first
Slide 6: Opportunity for Therapeutics Targeting Basal Forebrain Cholinergic Degeneration
Opportunity for Therapeutics Targeting Basal E | P Forebrain Cholinergic Degeneration PHARMA Age-related degeneration of the basal forebrain cholinergic system plays major i role in many neurologic disorders: cor Basal Forebrain — Dementia with Lewy bodies (DLB), where it is the primary pathology Pa
Slide 7: EIP Pharma Pipeline
EIP Pharma Pipeline rd ~) EIP Comm. Rights NEFLAMAPIMOD bodies* Recovery after Anterior wor PEASESIREADY Circulation Ischemic Stroke PRECLINICAL PHASE1 PHASE2 PHASE3 Early-onset Alzheimer’s Disease (EOAD) ww EIP200 (novel co-crystal) amees - *Received FDA Fast Track designation
Slide 8: Dementia with Lewy Bodies (DLB)
Dementia with Lewy Bodies (DLB) Le Affects ~1.4 million individuals in + Disease associated with abnormal deposits of a protein called alpha-synuclein in the brain. These deposits, called Lewy bodies, affect chemicals in the brain the US and EU whose changes, in turn, can lead to problems with think
Slide 9: Neflamapimod for DLB: Well-Positioned Commercially
Neflamapimod for DLB: Well-Positioned E | P Commercially PHARMA Approximately 700,000 in each of « eu © Numbers Diagnosed and managed : Increasing awareness by neurologists B >$5B Peak Sales of disease for the First to Market Relative to AD: * Greater rate of cognition decline i Bullds on Existing H
Slide 10: Neflamapimod: Background
Neflamapimod: Background + Potent, highly selective, blood-brain-barrier penetrant oral small molecule inhibitor of p38a. * Licensed in 2014 from Vertex Pharmaceuticals, which had: — Discovered the compound utilizing their proprietary structure-based drug discovery platform — Completed chronic repea
Slide 11: Robust Preclinical Pharmacology Package
Robust Preclinical Pharmacology Package E | P PHARMA In Ts2 mice 4 weeks neflamapimod () th In Vitro treatment FeVErSeS neurodegenerative process in the basal forebrain and Demonstrated potent effects, with ICsy restores functional deficits (Nat between 20nM and 30nM Communications, 2022) ‘ d + Reve
Slide 12: Neflamapimod Reverses Cholinergic Dysfunction and Degeneration
Neflamapimod Reverses Cholinergic Dysfunction and Degeneration Ts2mice * Down Syndrome transgenic mouse model * Develop adult-onset basal forebrain cholinergic degeneration * Treated with vehicle or 3 mg/kg NFMD BID x 28 days Reversed basal forebrain cholinergic neuron loss and restored cholinergic
Slide 13: Neflamapimod Appears to Reverse Basal Forebrain Atrophy, assessed by MRI
Neflamapimod Appears to Reverse Basal E | P Forebrain Atrophy, assessed by MRI PHARMA Neflamapimod treatment is associated with increased basal forebrain volume and functional connectivity 15 Early AD patients bd i a treated with neflamapimod Mal WK) t + Baseline 12 weeks Follow-up treatment cor
Slide 14: Neflamapimod: Toxicology, Safety, Efficacy, Development Status
Neflamapimod: Toxicology Clinical Safety Clinical Efficacy Development Status E | P PHARMA * Completed long-term toxicology studies in two species + At 40 mg thrice daily in humans greater than 10-fold safety margin to no-adverse- event level in long-term animal toxicity studies + Simple 3-step drug
Slide 15: Target Engagement: Neflamapimod Reduces CSF tau levels in Early AD
Target Engagement: Neflamapimod Reduces Cerebrospinal fluid (CSF) tau levels in patients with Early AD E | P PHARMA In preclinical studies, inhibition of p38a reduces Clinical Trial Results with Neflamapimod ‘tau phosphorylation and aggregation CTT Selective suppression of the a isoform of | & p38 M
Slide 16: Phase 2a Exploratory Clinical Study in DLB
Phase 2a Exploratory Clinical Study in Dementia with Lewy Bodies (DLB) GiscenD-LB Patients + Mild-to-Moderate DLB by consensus criteria (Mckeith, Neurology, 2017) + Abnormal dopamine uptake by DaTscan™ + Onbackground cholinesterase inhibitor NFMD 40 mg or matching placebo EIP PHARMA Cutcome Measures
Slide 17: AscenD-LB Outcome Measures
AscenD-LB Outcome Measures GscenD-LB Clinical Dementia Rating Sum of Boxes (CDR-SB, Total Score = 0-18) Cognitive Domains: + Memory (0-3) * Orientation (0-3) + Judgement and Reasoning (0-3) Functional Domains: * Community Affairs (0-3) + Home & Hobbies (0-3) + Personal Care (0-3) Neuropsychological
Slide 18: AscenD-LB demonstrated neflamapimod significantly improved cognition and function
AscenD-LB demonstrated neflamapimod significantly improved cognition and function in mild-to-moderate DLB GscenD-LB 40mg BID + 40mg TID 40mg TID ‘Mean vs. placebo Mean vs. placebo Name Measure sxc) Pveve sxc) weve ClinicelDementia Rating as +) 056 (+) Dementia Sever 0028 0.007 Y sum of Boxes (CORSE)
Slide 19: Biomarker Results Support Enrichment Strategy for Future Trials
Biomarker Results Support Enrichment Strategy for Future Trials * 35-50% of patients with DLB have biomarker evidence of Alzheimer’s disease (AD) — Represent patients with extensive neurodegeneration (neuronal loss) in the cerebral cortex, particularly in the medial temporal lobe (i.e., inthe hippoc
Slide 20: Learnings from Phase 2a Study That Enhance Probability of Success in Phase 2b
Learnings from Phase 2a Study That Enhance E | P Probability of Success in Phase 2b PHARMA * Optimal dose is 40mg TID * Clinical endpoints that can detect effects on both cognitive and motor function (specifically, CDR-SB and TUG) perform better than endpoints that are purely focused on evaluating c
Slide 21: Phase 2b Confirmatory Study in DLB
Phase 2b Confirmatory Study in DLB Protocol EIP21-NFD-504 Patients DLB by consensus criteria (McKeith, Neurology, 2017) Abnormal dopamine uptake by DaTscan™ Onbackground cholinesterase inhibitor therapy or naive Global CDR <2.0 ptaut81 <2.4 pgiml (ie, no AD co-pathology) 160 patients (randomized 1:1
Slide 22: Potential to Broaden Opportunity
Potential to Broaden Opportunity E | P PHARMA * Additional indications in which dysfunction or degeneration of basal forebrain cholinergic system plays major pathogenic role: — Functional recovery after anterior circulation ischemic stroke — Alzheimer’s disease (AD): Early-onset AD (EOAD) or Late On
Slide 23: Leadership Team
Leadership Team John Alam, MD President, CEO & Co-Founder std, uibtex * Biogen Sylvie Gregoire, PharmD Executive Chair & Co-Founder €> merck * Biogen hire $n, 2. William Tanner, PhD Chief Financial Orficer B....%. LAZARD Sylvie Grégoire, PrarmD: Exzoutve hae JJohnAlsm, MO: Present & CEO ‘Jeff Pouton
Slide 24: Key Upcoming Anticipated Milestones/Catalysts
Key Upcoming Anticipated E | Pp Milestones/Catalysts PHARMA ¥ N\A approves $21M grant for Q_ Close merger transaction; Q > Complete enrolment in Phase Phase 2b begin trading as a public 2b DLB study (1H) company (mid-year) ¥ Signed merger agreement Q_ Report data from placebo- with Diffusion Pharma
Slide 25: Summary
Summary E | P PHARMA @ Differentiated Approach to Age-related Neurologic Disorders with a Late-Stage Asset Major value creation potential in phase 2b read-out in dementia with Lewy bodies EIP Experienced Management Team and Board of Directors Potential to broaden opportunity through additional indic
Slide 26: Thank you
Thank you \